Phenylpiracetam, Fasoracetam & Racetams: What the Research Shows

Racetams are a broad family of synthetic compounds that have attracted attention for decades because of claims involving memory, cognition, neurological function and so-called nootropic effects.

The best-known member is piracetam, but the broader family includes compounds such as phenylpiracetam, oxiracetam, aniracetam, pramiracetam and fasoracetam.

Despite their popularity in online nootropic communities, these compounds should not be treated as one interchangeable group. Their chemistry, proposed mechanisms, research histories and regulatory status differ considerably.

Human clinical evidence is also uneven. Some older racetams have been investigated in neurological disorders, while compounds such as fasoracetam have only limited clinical trial data in highly specific populations. Reviews of the class describe mixed clinical findings and note that the mechanisms of many racetams remain incompletely understood.

For more evidence-focused supplement and pharmacology resources, visit Chemiderm.com.

What Are Racetams?

The term racetam usually refers to a family of compounds structurally related to piracetam.

Commonly discussed examples include:

• Piracetam
• Phenylpiracetam
• Aniracetam
• Oxiracetam
• Pramiracetam
• Fasoracetam
• Coluracetam

Researchers have investigated various racetams for possible effects involving:

• Memory
• Cognition
• Neurological disorders
• Seizures
• Neuroprotection
• Glutamate signalling

However, evidence differs dramatically from one compound to another.

A finding involving piracetam should not automatically be applied to phenylpiracetam or fasoracetam.

What Is Piracetam?

Piracetam is the original and most historically studied racetam.

It helped establish the broader concept of a “nootropic”—a substance proposed to support cognition without functioning like a traditional stimulant.

Research has investigated piracetam in areas including:

• Cognitive impairment
• Cerebrovascular disorders
• Myoclonus
• Brain injury
• Neuroprotection

A major review of piracetam-like compounds concluded that clinical outcomes were variable and that the underlying mechanisms remained difficult to define conclusively.

Piracetam therefore provides useful historical context, but it should not be treated as proof that all racetams enhance cognition in healthy people.

What Is Phenylpiracetam?

Phenylpiracetam, also known as fonturacetam or 4-phenylpiracetam, is a modified derivative of piracetam.

The addition of a phenyl group changes its physical and pharmacological characteristics.

It has been investigated for possible effects involving:

• Cognition
• Fatigue
• Neurological recovery
• Mood-related symptoms
• Neuroprotection
• Physical performance

A 2024 review discussed possible applications in areas such as cerebral ischemia, neurodegenerative conditions, epilepsy, asthenia and mental disorders, but much of the evidence base includes experimental work and studies that require further confirmation.

This means phenylpiracetam should not be presented as a universally proven cognitive enhancer.

Phenylpiracetam vs Piracetam

Phenylpiracetam is structurally related to piracetam but is not simply the same compound at a higher strength.

The modification may affect:

• Brain penetration
• Pharmacological potency
• Stimulant-like activity
• Neurotransmitter effects
• Duration

Older reviews generally describe phenylpiracetam as more potent than piracetam in certain experimental contexts, but high-quality modern comparative trials remain limited.

Is Phenylpiracetam a Stimulant?

Phenylpiracetam has stimulant-like properties significant enough to matter in competitive sport.

The 2026 World Anti-Doping Agency Prohibited List includes fonturacetam, identified as 4-phenylpiracetam or carphedon, under S6.A non-specified stimulants prohibited in competition.

This is especially important for competitive athletes.

A substance marketed online as a “nootropic” may still have consequences under anti-doping rules.

What Is Fasoracetam?

Fasoracetam is another racetam-related compound, but its research profile is quite different.

It has been studied as an investigational compound affecting metabotropic glutamate receptor signalling, rather than simply being treated as another version of piracetam.

One small clinical study examined fasoracetam in 30 adolescents with ADHD who had genetic variants affecting the metabotropic glutamate receptor network. The study reported improvements in several clinical measures, particularly among certain genetically defined subgroups.

However, this was a small, specialized study and does not establish fasoracetam as a general ADHD treatment or cognitive enhancer.

Fasoracetam and ADHD Research

The fasoracetam ADHD study is often cited online, but its design and population matter.

Participants were:

• Adolescents aged 12–17
• Diagnosed with ADHD
• Selected for genetic variants affecting mGluR signalling
• Enrolled in a short-duration clinical study

The research was exploratory and focused heavily on safety, pharmacokinetics and signals of response in a genetically selected population.

That is very different from demonstrating effectiveness for healthy adults seeking cognitive enhancement.

How Might Fasoracetam Work?

Fasoracetam has been studied in relation to metabotropic glutamate receptors, commonly abbreviated mGluRs.

Glutamate is the brain’s principal excitatory neurotransmitter.

Metabotropic glutamate receptors are involved in:

• Neural communication
• Synaptic signalling
• Learning
• Memory
• Neurodevelopment

The clinical fasoracetam study described it as an mGluR activator and explored whether this pathway could be useful in a genetically defined ADHD subgroup.

More research is required before broad clinical conclusions can be drawn.

Racetams and Glutamate

Glutamatergic signalling is one of the major themes in racetam research.

Some racetams have been proposed to influence AMPA receptor-mediated signalling.

AMPA receptors are glutamate receptors involved in fast excitatory neurotransmission.

A review of positive AMPA-receptor modulators describes several racetams—including piracetam, oxiracetam, pramiracetam, aniracetam and phenylpiracetam—as compounds associated with modulation of AMPA-related signalling.

However, different racetams can have different molecular actions.

It would therefore be inaccurate to say that every racetam works through exactly the same receptor.

What Are AMPA Receptors?

AMPA receptors respond to glutamate and play important roles in:

• Synaptic communication
• Learning
• Memory
• Neural plasticity

Because these systems are important for cognition, researchers have long been interested in compounds capable of modulating AMPA-related transmission.

That scientific interest is one reason racetams became associated with cognitive enhancement.

But a biologically plausible mechanism does not automatically prove meaningful cognitive improvement in humans.

Aniracetam

Aniracetam is another frequently discussed racetam.

Experimental and older clinical literature has explored possible effects involving cognition and glutamatergic signalling.

However, the quality, age and applicability of the human evidence vary significantly.

Claims that aniracetam reliably improves memory or anxiety in healthy users often go beyond what modern high-quality clinical research establishes.

Oxiracetam

Oxiracetam is another piracetam-related compound that has been studied for possible cognitive effects.

Like other racetams, it has appeared in research involving neurological or cognitive impairment.

However, there is limited modern evidence demonstrating clinically meaningful benefits for healthy people.

This distinction matters because much of online nootropic marketing extrapolates from disease research into healthy cognitive enhancement.

Those are not equivalent claims.

Pramiracetam

Pramiracetam is a synthetic racetam derivative historically investigated in cognitive disorders and neurological injury.

Older reviews discuss possible benefits in selected patient populations, but evidence remains limited and heterogeneous.

More contemporary, high-quality trials would be needed to support broad claims.

Coluracetam

Coluracetam is another compound frequently included in online racetam lists.

Its human research base is much smaller than that of piracetam.

Consumers should therefore be particularly careful about promotional claims describing it as an established cognitive enhancer.

Limited research does not necessarily mean a compound is ineffective—but it does mean confident claims are difficult to justify.

Do Racetams Improve Memory?

There is no single answer.

Evidence depends on:

• Which racetam is studied
• Whether participants are healthy or medically impaired
• Which cognitive test is used
• Duration of treatment
• Study quality
• Sample size

The older racetam literature includes positive findings in selected neurological populations, but results are inconsistent across compounds and conditions.

There is much less high-quality evidence supporting routine racetam use simply to make healthy people “smarter.”

Are Racetams Proven Nootropics?

The term nootropic is used loosely online.

Scientifically, a useful question is not whether a product is called a nootropic but whether controlled human trials demonstrate meaningful benefits.

For racetams:

• Some compounds have clinical research.
• Some have mostly experimental data.
• Some have very limited human evidence.
• Mechanisms remain incompletely understood.
• Evidence quality varies widely.

Therefore, it is more accurate to describe them as a heterogeneous class of investigational or historically studied cognitive compounds than as universally proven brain boosters.

Phenylpiracetam and Athletic Performance

Competitive athletes should pay special attention to phenylpiracetam.

WADA’s 2026 prohibited list identifies fonturacetam [4-phenylpiracetam (carphedon)] as a prohibited in-competition stimulant.

This means a supplement marketed for focus or performance could create an anti-doping violation.

Athletes should verify every supplement against current anti-doping rules rather than trusting product advertising.

Are Racetams FDA-Approved in the United States?

This is an important regulatory issue.

The FDA stated in a 2023 enforcement case that drugs containing racetams—including piracetam, aniracetam, coluracetam and phenylpiracetam—had not been approved by FDA for use in the United States.

An earlier FDA warning letter also stated that products including aniracetam, oxiracetam, phenylpiracetam, piracetam and pramiracetam were not conventional foods or dietary supplements for the purposes addressed in that enforcement action.

This makes regulatory status an essential part of any responsible racetam guide.

What About Fasoracetam?

The FDA’s substance database identifies fasoracetam and its synonyms such as NFC-1 and AEVI-001, but the agency explicitly notes that inclusion in the substance database does not imply regulatory review or approval.

Being catalogued by FDA is therefore not the same as being an approved medication.

Why “Sold Online” Does Not Mean “Approved”

A product being available from an online seller does not prove that it is:

• FDA-approved
• Legally marketed as a dietary supplement
• Clinically effective
• Pharmaceutical grade
• Tested for purity

FDA has taken enforcement action involving companies marketing unapproved racetam products.

Regulatory status should always be checked separately from commercial availability.

Nootropic Supplement Quality

One major issue in the nootropic market is undeclared or unauthorized pharmacological ingredients.

A 2023 review found that products marketed as nootropics can contain compounds with complex regulatory status, including pharmaceutical agents, investigational substances and doping-related compounds.

This makes independent product testing particularly important.

What Should Consumers Check?

For legal supplements and nootropic products, consider:

Ingredient Transparency

Every active ingredient should be clearly identified.

Regulatory Status

Check whether the substance is actually permitted in your jurisdiction.

Third-Party Testing

Independent testing can help assess identity and contamination.

Evidence Quality

Look for controlled human research rather than anecdotes alone.

Medical Interactions

Compounds affecting the nervous system may interact with medicines or health conditions.

Racetams and Safety

The safety database differs by compound.

Older research described some racetams as generally well tolerated, but this should not be generalized to every compound or unregulated online product.

Potential concerns include:

• Headache
• Sleep disturbances
• Anxiety
• Gastrointestinal symptoms
• Unknown long-term effects
• Medication interactions
• Product contamination or mislabelling

The lack of extensive long-term safety data is especially important for newer or poorly studied racetams.

Does “Research Chemical” Mean Safe?

No.

A compound described as a research chemical or experimental nootropic may simply have less clinical evidence, not more.

Less evidence means there may be greater uncertainty about:

• Appropriate medical use
• Long-term safety
• Interactions
• Toxicity
• Purity of commercial material

Scientific uncertainty should not be mistaken for safety.

Phenylpiracetam vs Fasoracetam

These compounds are both discussed within the racetam family, but their research profiles are different.

Phenylpiracetam

• Derivative of piracetam
• Also called fonturacetam
• Has stimulant-like properties
• Appears on the WADA prohibited list
• Clinical evidence remains limited and heterogeneous

Fasoracetam

• Investigational racetam
• Studied in relation to metabotropic glutamate signalling
• Small clinical study conducted in genetically selected adolescents with ADHD
• Not established as a general cognitive-enhancement treatment

Treating the two as interchangeable would be scientifically inaccurate.

Racetam Research at a Glance

Compound	Main Research Theme	Evidence Status
Piracetam	Neurological and cognitive disorders	Long research history, mixed results
Phenylpiracetam	Cognition, fatigue, neurological conditions	Limited/moderate research, regulatory concerns
Fasoracetam	mGluR signalling, experimental ADHD research	Small specialized clinical evidence
Aniracetam	Cognition, AMPA-related signalling	Older and limited evidence
Oxiracetam	Cognitive impairment	Limited modern evidence
Pramiracetam	Cognition and neurological injury	Limited evidence
Coluracetam	Experimental cognitive research	Very limited human data

Can Racetams Replace ADHD Medication?

No.

A small fasoracetam study in a genetically defined ADHD subgroup does not establish racetams as replacements for evidence-based ADHD treatment.

Current ADHD treatments have much larger clinical evidence bases.

Medication changes should be made with an appropriate healthcare professional.

Can Racetams Replace Dementia Treatment?

No.

Research interest in cognition does not mean these compounds should replace established treatment for:

• Alzheimer’s disease
• Dementia
• Stroke
• Brain injury
• Epilepsy

Clinical decisions should be based on diagnosis-specific evidence rather than general “brain booster” claims.

Racetams vs Bacopa Monnieri

Bacopa and racetams belong to very different categories.

Bacopa Monnieri

A botanical extract containing naturally occurring constituents such as bacosides.

Racetams

Synthetic compounds derived historically from piracetam-like chemistry.

Our Bacopa monnieri benefits guide covers the botanical side of the cognitive-support market separately.

How This Fits Into the Chemiderm Nootropics Hub

This page expands the nootropics cluster on Chemiderm.com.

Related resources include:

• Bacopa monnieri benefits
• Racetams and nootropics
• Phenylpiracetam
• Fasoracetam
• Vitamin D3 and K2
• GABA and neurotransmitters
• Serotonin and brain signalling
• Cognitive supplements
• Supplement quality and safety

Separating individual compounds allows each page to target a specific search intent without keyword cannibalization.

Frequently Asked Questions

What are racetams?

Racetams are a family of synthetic compounds structurally related to piracetam and historically investigated for cognitive and neurological effects.

Is phenylpiracetam the same as piracetam?

No. Phenylpiracetam is a modified piracetam derivative with different pharmacological characteristics.

Is phenylpiracetam banned in sport?

Yes. The 2026 WADA Prohibited List includes fonturacetam, also identified as 4-phenylpiracetam or carphedon, among stimulants prohibited in competition.

What is fasoracetam?

Fasoracetam is an investigational racetam-related compound studied partly for its effects on metabotropic glutamate receptor signalling.

Has fasoracetam been studied for ADHD?

Yes. A small study investigated it in adolescents with ADHD and specific genetic variants affecting glutamatergic signalling, but that does not establish it as a standard ADHD treatment.

Are racetams FDA-approved in the United States?

FDA has stated that racetam drugs such as piracetam, aniracetam, coluracetam and phenylpiracetam are not FDA-approved for use in the United States.

Do racetams improve memory?

Some studies involving certain racetams and patient populations have reported benefits, but the overall evidence is mixed and varies substantially by compound.

Are racetams safe?

Safety data vary by compound, and long-term information is limited for several of them. Online availability should not be interpreted as proof of safety or approval.

Final Thoughts

The term racetams covers a diverse group of compounds rather than one standardized nootropic.

Piracetam has the longest history, while phenylpiracetam, fasoracetam, oxiracetam, aniracetam, pramiracetam and coluracetam each have distinct research profiles.

Some mechanistic research points toward glutamatergic signalling and AMPA-related activity, while fasoracetam has specifically been studied in relation to mGluR pathways. Yet clinical evidence remains mixed and uneven across the class.

Regulatory status is also crucial. FDA has taken action involving unapproved racetam products, and competitive athletes should know that phenylpiracetam remains prohibited in competition under the 2026 WADA list.

For more evidence-focused nootropic, supplement and neuroscience content, visit Chemiderm.com.